Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance

Detalhes bibliográficos
Autor(a) principal: Leonardo-Sousa, Carlota
Data de Publicação: 2022
Outros Autores: Carvalho, Andreia Neves, Guedes, Romina A., Fernandes, Pedro M. P., Aniceto, Natália, Salvador, Jorge A. R., Gama, Maria João, Guedes, Rita C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/103390
https://doi.org/10.3390/molecules27072201
Resumo: Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies. However, initial response to the therapy is a challenge as most patients show an innate resistance to proteasome inhibitors, and those that respond to the therapy usually develop late relapses suggesting the development of acquired resistance. The mechanisms of resistance to proteasome inhibition are still controversial and scarce in the literature. In this review, we discuss the development of proteasome inhibitors and the mechanisms of innate and acquired resistance to their activity-a major challenge in preclinical and clinical therapeutics. An improved understanding of these mechanisms is crucial to guiding the design of new and more effective drugs to tackle these devastating diseases. In addition, we provide a comprehensive overview of proteasome inhibitors used in combination with other chemotherapeutic agents, as this is a key strategy to combat resistance.
id RCAP_f00c94ef42dd71bb56be48c6dcd5ed55
oai_identifier_str oai:estudogeral.uc.pt:10316/103390
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistanceubiquitin–proteasome pathwayproteasome inhibitorsmechanisms of resistanceinnate resistanceacquired resistancemultiple myelomacancerAdultBortezomibHumansProteasome Endopeptidase ComplexProteasome InhibitorsQuality of LifeAntineoplastic AgentsMultiple MyelomaNeoplasmsProteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies. However, initial response to the therapy is a challenge as most patients show an innate resistance to proteasome inhibitors, and those that respond to the therapy usually develop late relapses suggesting the development of acquired resistance. The mechanisms of resistance to proteasome inhibition are still controversial and scarce in the literature. In this review, we discuss the development of proteasome inhibitors and the mechanisms of innate and acquired resistance to their activity-a major challenge in preclinical and clinical therapeutics. An improved understanding of these mechanisms is crucial to guiding the design of new and more effective drugs to tackle these devastating diseases. In addition, we provide a comprehensive overview of proteasome inhibitors used in combination with other chemotherapeutic agents, as this is a key strategy to combat resistance.MDPI2022-03-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/103390http://hdl.handle.net/10316/103390https://doi.org/10.3390/molecules27072201eng1420-3049Leonardo-Sousa, CarlotaCarvalho, Andreia NevesGuedes, Romina A.Fernandes, Pedro M. P.Aniceto, NatáliaSalvador, Jorge A. R.Gama, Maria JoãoGuedes, Rita C.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-11-11T21:39:35Zoai:estudogeral.uc.pt:10316/103390Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:20:14.266427Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
title Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
spellingShingle Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
Leonardo-Sousa, Carlota
ubiquitin–proteasome pathway
proteasome inhibitors
mechanisms of resistance
innate resistance
acquired resistance
multiple myeloma
cancer
Adult
Bortezomib
Humans
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Quality of Life
Antineoplastic Agents
Multiple Myeloma
Neoplasms
title_short Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
title_full Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
title_fullStr Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
title_full_unstemmed Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
title_sort Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
author Leonardo-Sousa, Carlota
author_facet Leonardo-Sousa, Carlota
Carvalho, Andreia Neves
Guedes, Romina A.
Fernandes, Pedro M. P.
Aniceto, Natália
Salvador, Jorge A. R.
Gama, Maria João
Guedes, Rita C.
author_role author
author2 Carvalho, Andreia Neves
Guedes, Romina A.
Fernandes, Pedro M. P.
Aniceto, Natália
Salvador, Jorge A. R.
Gama, Maria João
Guedes, Rita C.
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Leonardo-Sousa, Carlota
Carvalho, Andreia Neves
Guedes, Romina A.
Fernandes, Pedro M. P.
Aniceto, Natália
Salvador, Jorge A. R.
Gama, Maria João
Guedes, Rita C.
dc.subject.por.fl_str_mv ubiquitin–proteasome pathway
proteasome inhibitors
mechanisms of resistance
innate resistance
acquired resistance
multiple myeloma
cancer
Adult
Bortezomib
Humans
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Quality of Life
Antineoplastic Agents
Multiple Myeloma
Neoplasms
topic ubiquitin–proteasome pathway
proteasome inhibitors
mechanisms of resistance
innate resistance
acquired resistance
multiple myeloma
cancer
Adult
Bortezomib
Humans
Proteasome Endopeptidase Complex
Proteasome Inhibitors
Quality of Life
Antineoplastic Agents
Multiple Myeloma
Neoplasms
description Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies. However, initial response to the therapy is a challenge as most patients show an innate resistance to proteasome inhibitors, and those that respond to the therapy usually develop late relapses suggesting the development of acquired resistance. The mechanisms of resistance to proteasome inhibition are still controversial and scarce in the literature. In this review, we discuss the development of proteasome inhibitors and the mechanisms of innate and acquired resistance to their activity-a major challenge in preclinical and clinical therapeutics. An improved understanding of these mechanisms is crucial to guiding the design of new and more effective drugs to tackle these devastating diseases. In addition, we provide a comprehensive overview of proteasome inhibitors used in combination with other chemotherapeutic agents, as this is a key strategy to combat resistance.
publishDate 2022
dc.date.none.fl_str_mv 2022-03-28
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/103390
http://hdl.handle.net/10316/103390
https://doi.org/10.3390/molecules27072201
url http://hdl.handle.net/10316/103390
https://doi.org/10.3390/molecules27072201
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1420-3049
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134095231418368